Patient Support & Resources for Your Practice

 

IPSEN CARES® (Coverage, Access, Reimbursement & Education Support) serves as a central point of contact between patients, caregivers, doctors’ offices, insurance companies, and specialty pharmacies.

Help patients navigate the insurance coverage process to determine out-of-pocket costs for treatment

Help with copay assistance for eligible* patients

Provide information on Nurse Home Health Administration

 

Provide free medication to eligible patients through the Patient Assistance Program

Help minimize delays or interruptions to treatment

Coordinate medication deliveries through specialty pharmacies

 

Learn more at IPSENCARES.com

*Please see Patient Eligibility & Terms and Conditions.

 

Ipsen Cares

A Range of Tools to Help Your Patients

These downloadable resources are intended to provide you and your practice with helpful information.

Downloadable resources

NETs Neuroendocrine Expert Talks Podcast Series

Listen to diagnostic and treatment advice from key opinion leaders as they discuss hypothetical patient scenarios.

The healthcare professionals in these podcasts are paid consultants for Ipsen.

Play Podcast

 

Pancreatic NET
Patient Case Study

Download

Midgut NET
Patient Case Study

Download

Carcinoid Syndrome
Patient Case Study

Download

The above case study is hypothetical.

Videos

View these videos for insights into specific aspects of Somatuline Depot.

How to Administer a Somatuline Depot Injection

Watch a healthcare professional demonstrate how to administer a deep subcutaneous injection with the redesigned Somatuline Depot syringe.

Liquid Crystal Formulation1-4

Learn about the formulation of Somatuline Depot, wherein a high density of nanotubes self-assemble to form a depot that functions as a reservoir for the drug between extended doses.

IMPORTANT SAFETY INFORMATION & INDICATIONS

Contraindications

  • SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.

Warnings and Precautions

  • Cholelithiasis and Gallbladder Sludge
    • SOMATULINE DEPOT may reduce gallbladder motility and lead to gallstone formation.
    • Periodic monitoring may be needed.
    • If complications of cholelithiasis are suspected, discontinue SOMATULINE DEPOT and treat appropriately.
  • Hypoglycemia or Hyperglycemia
    • Patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia.
    • Blood glucose levels should be monitored when SOMATULINE DEPOT treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.
  • Cardiovascular Abnormalities
    • SOMATULINE DEPOT may decrease heart rate.
    • In patients without underlying cardiac disease, SOMATULINE DEPOT may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia.
    • In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. Care should be taken when initiating treatment in patients with bradycardia.

Most Common Adverse Reactions

  • GEP-NETsAdverse reactions in >10% of patients who received SOMATULINE DEPOT were abdominal pain (34%), musculoskeletal pain (19%), vomiting (19%), headache (16%), injection site reaction (15%), hyperglycemia (14%), hypertension (14%), and cholelithiasis (14%).
  • Carcinoid SyndromeAdverse reactions occurring in the carcinoid syndrome trial were generally similar to those in the GEP-NET trial. Adverse reactions in ≥5% of patients who received SOMATULINE DEPOT and at least 5% greater than placebo were headache (12%), dizziness (7%) and muscle spasm (5%).

Drug Interactions 

  • SOMATULINE DEPOT may decrease the absorption of cyclosporine (dosage adjustment may be needed); increase the absorption of bromocriptine; and require dosage adjustment for bradycardia-inducing drugs (e.g., beta-blockers).

Special Populations

  • LactationAdvise women not to breastfeed during treatment and for 6 months after the last dose.

To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS

SOMATULINE® DEPOT (lanreotide) is a somatostatin analog indicated for:

  • the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; and
  • the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.

Please click here for the full Prescribing Information and Patient Information.

References: 1. Data on file. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; 2007. 2. Wolin EM, Manon A, Chassaing C, et al. Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J Gastrointest Canc. 2016;47(4):366-374. 3. Pandit A, Fay N, Bordes L, et al. Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues. J Pept Sci. 2008;14(1):66-75. 4Somatuline Depot (lanreotide) Injection [Prescribing Information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; June 2019. 5. Adelman DT, Truong Thahn X-M, Mégret C. Enhancing patient care: co-creation and validation of a new and improved delivery system for lanreotide autogel/depot and its evaluation by US healthcare professionals. Presented at the 101st Annual Meeting and Expo of the Endocrine Society. New Orleans, LA; March 23-26, 2018. 6. Data on file. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; 2018. This study has been funded by Ipsen.

©2019 Ipsen Biopharmaceuticals, Inc. All rights reserved. March 2019 SMD-US-002660

Are you a healthcare provider?

This site is intended for U.S. healthcare providers only.

By clicking YES, you attest you are a healthcare provider licensed in the U.S.

YES   NO